Overall survival estimates adjusted for Zubrod performance status, high-risk group (ie, extracapsular extension, positive margins), and primary tumor site among patients in this study (ie, Radiation Therapy Oncology Group [RTOG] 0024) compared with those in the radiation therapy (RT) plus chemotherapy (CT) group of RTOG 9501.